Group 1 - InxMed Limited-B, also known as 应世生物, submitted its Hong Kong IPO application on August 25, 2025, which will expire on February 25, 2026 [1] - The company is a late-stage biotechnology firm established in 2017, focused on improving the efficacy of current cancer treatment options [2] - InxMed aims to address the core challenges of cancer treatment, particularly drug resistance caused by tumor defenses [2] Group 2 - The company focuses on key signaling pathways common across various tumor types, especially the FAK and integrin pathways, which play a critical role in tumor cell survival [2] - InxMed targets cancer-associated fibroblasts (CAFs) to dismantle the protective barriers surrounding tumor cells [2] - By targeting key pathways related to drug resistance, InxMed seeks to reshape rational drug use in cancer treatment and open new frontiers for therapeutic innovation [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional materials from InxMed Limited, a biotech company aiming for a Hong Kong IPO, focusing on shareholder contributions, compliance with regulations, and financial disclosures [1][2][3][4]. Group 1: Regulatory Compliance - The CSRC has asked InxMed to clarify the compliance of its offshore structure and return investment with respect to foreign exchange management, overseas investment, and tax regulations [2]. - The company must provide a legal opinion on the pricing basis and payment methods for acquiring domestic operational entities, ensuring compliance with regulations regarding foreign investment in domestic enterprises [2]. Group 2: Shareholder and Equity Changes - InxMed is required to verify the stock options granted to external consultants and assess whether any shareholders are prohibited from holding shares under relevant laws [3]. - The company must justify the reasonableness of the share price for new shareholders over the past 12 months and investigate any anomalies in the share contributions [3]. Group 3: Domestic Operations - The company needs to explain the reasons for its capital reduction in Nanjing and confirm that there are no issues of false contributions or capital withdrawal, ensuring compliance with the Company Law and tax regulations [3]. - A review of the legality of historical equity holding arrangements in Beijing is also required [3]. Group 4: Business Operations - InxMed must clarify whether its business activities involve restricted areas such as human stem cells and gene diagnosis and treatment, ensuring compliance with foreign investment policies [4]. - The company is also required to supplement its financial status in the filing report with net asset data [4]. Group 5: Financial Performance - InxMed reported net revenues of approximately -392,000 yuan, 2.472 million yuan, and 1.603 million yuan for 2023, 2024, and Q1 2025 respectively, with losses of 209 million yuan, 185 million yuan, and 3.369 million yuan during the same periods [5][6]. - The company has been operating at a loss since its inception and cannot guarantee future revenue or profitability, with significant ongoing R&D expenses expected [6].

Group 1: Recent IPOs on Hong Kong Stock Exchange - Two companies listed on the Hong Kong Stock Exchange from August 25 to August 31 [2] - Shuangdeng Group Co., Ltd. (6960.HK) listed on August 26, focusing on energy storage batteries, with a first-day increase of 31.29% and a market cap of approximately HKD 73 billion [3] - Jiaxin International Resources Investment Co., Ltd. (3858.HK) listed on August 28, specializing in tungsten mining, with a first-day increase of 177.84% and a market cap of approximately HKD 148 billion [3] Group 2: New Stock Offerings - One company completed its new stock offering during the week of August 25 to August 31 [4] - Aux Electric, a global provider of high-quality air conditioning solutions, went through the listing hearing [5] Group 3: Companies Submitting Listing Applications - A total of 22 companies submitted main board listing applications and one company submitted a GEM listing application from August 25 to August 31 [7] - Notable companies include: - Nazhen Technology, a global provider of optical communication solutions, submitted its application on August 25 [8] - Chengdu Guoxing Aerospace Technology Co., Ltd., a participant in China's commercial aerospace industry, submitted its application on August 25 [9] - InxMed Limited-B, a biotech company focused on cancer treatment, submitted its application on August 25 [9] Group 4: Financial Performance and Projections - Nazhen Technology projected revenues of CNY 5.043 billion, CNY 4.239 billion, and CNY 5.087 billion from 2022 to 2024, with profits of CNY 429 million, CNY 216 million, and CNY 89 million respectively [18] - Guoxing Aerospace projected revenues of CNY 177 million, CNY 508 million, and CNY 553 million from 2022 to 2024, with losses of CNY 91 million, CNY 139 million, and CNY 177 million respectively [20] - InxMed Limited-B reported no commercial sales revenue for 2023 and 2024, with losses of CNY 209 million and CNY 185 million respectively [23] Group 5: Industry Insights - The energy storage battery market is growing, with Shuangdeng Group focusing on applications in communication base stations and data centers [3] - The tungsten mining sector is highlighted by Jiaxin International, which is developing the Bakuta tungsten mine in Kazakhstan [3] - The optical communication sector is represented by Nazhen Technology, which ranks fifth globally in optical module revenue [18]